| Margins | Shifting to own brands (70%) and oncology to enhance profitability. |
|---|---|
| Order book | 300+ dossiers in process; 32 oncology dossiers ready for launch. |
| Demand visibility | Driven by rising global cancer incidence and 60+ country presence. |
| Management confidence | High focus on onco-led value creation and vertical integration. |
Growth
Oncology margins are projected at ~2x general formulations; aiming for 70% revenue from own brand exports.
Outlook
Targets 300+ dossier approvals and 100+ overseas contracts within 2 years; focus on complex liposomal/HME products.
Risks
Exposure to international market volatility, regulatory compliance in regulated markets, and intense competition in oncology.
Earnings Call filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,135.85
- Market cap
- ₹2,527 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 70.0×Sector 50.4×
- Promoter holding
- 52.52%-0.34% QoQ
- FII holding
- 12.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare Annual General Meeting
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
- Call
- Guides 100% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.
Sakar Healthcare Q1 FY27 Results: Net Profit ₹10.3 Cr, Up 119.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹73 Cr (+38.5% YoY) and net profit of ₹10.3 Cr (+119.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹10.3 Cr · +119.1% YoY
Sakar Healthcare Earnings Call: Key Takeaways
Sakar Healthcare Q4 FY26 revenue grew 42% YoY to ₹71.1cr with 37% EBITDA margins. Strategy focuses on transforming into a pure-play oncology exporter via its EU GMP facility.